Email this article BEVACIZUMAB USE IN METASTATIC COLORECTAL CANCER IN THE FACILITIES OF DAY HOSPITAL OF REGIONAL ОNCOLOGY DISPENSARY
- Authors: Malysheva T.A.1, Orlov O.A.2
-
Affiliations:
- Perm Regional Oncology Dispensary
- Academician E.A. Vagner Perm State Medical Academy, Ministry of Health of Russia
- Issue: Vol 3, No 3 (2014)
- Pages: 35-38
- Section: ORIGINAL REPORTS
- Published: 28.02.2015
- URL: https://onco-surgery.info/jour/article/view/78
- DOI: https://doi.org/10.17650/2220-3478-2014-0-3-35-38
- ID: 78
Cite item
Full Text
Abstract
Purpose. To conduct retrospective analysis of first line therapy with bevacizumab received by patients treated in Perm Regional Oncology Dispensary.
Methods. Analysis of treatment results of 28 patients who received first line metastatic colorectal cancer (mCRC) treatment including bevacizumab in Perm Regional Oncology Dispensary. Patients received bevacizumab 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks in combination with FOLFOX, XELOX or capecitabin monotherapy in first line treatment until disease progression. Patients continued bevacizumab with change of chemotherapy regimen after first disease progression if it was possible due to performance status.
Results. Disease control was reached in 21 (75 %) cases. Complete remission was detected in 3 (10.7 %) of patients, partial remission in 9 (32.15 %), disease stabilization in 9 (32.15 %) and disease progression in 7 (25.0 % ) of patients. Median time to progression was 12 months (from 4 to 36 months). R0 liver metastases resection was performed in 9 (35.7 %) patients after treatment. Median Overall Survival was 25 months.
Conclusions. The results of retrospective analysis are in line with the data of International Clinical Trials of bevacizumab in the mCRC therapy. Continuous bevacizumab treatment from first line with the following maintenance until disease progression and further continuation in second line treatment with the chemotherapy regimen change until progression made possible to increase the efficacy and survival of patients. Bevacizumab demonstrated good tolerability and did not increase toxicity of chemotherapy.
About the authors
T. A. Malysheva
Perm Regional Oncology Dispensary
Author for correspondence.
Email: Doctoron@mail.ru
Russian Federation
O. A. Orlov
Academician E.A. Vagner Perm State Medical Academy, Ministry of Health of Russia
Email: Doctoron@mail.ru
Russian Federation
References
Supplementary files
